Cancer Informatics Collaboratory
Home / Tools / eeDAP and FDA MDDT
Tool · Digital pathology · FDA MDDT

eeDAP and the FDA Medical Device Development Tools Program

eeDAP lets researchers show a pathologist the same spot on a glass slide and on its digital image, and compare their reads. FDA staff put it forward as a Medical Device Development Tool, and it was accepted into the program.

The research behind this page

  • Brandon D. Gallas, PhD: Research scientist in FDA CDRH's Division of Imaging, Diagnostics, and Software Reliability; led the eeDAP work and wrote the working-group posts. ✓ FDA presenter bio (PDF)

These researchers created the original work. They did not write or review this page. ✓ marks a credential or role confirmed on an official profile; "as listed" roles come from the original page. All researchers featured on this site.

Based on: 2 peer-reviewed papers, 1 government source, 1 official project or publisher site, 2 archived original pages. See all sources

Get eeDAP

Full name
Evaluation Environment for Digital and Analog Pathology
Made by
FDA CDRH, Division of Imaging, Diagnostics, and Software Reliability
License
Open source on GitHub
MDDT status
Proposal Oct 2016; accepted into the program as MDDT031 (2017)
Method paper
Gallas et al. 2014, Proc. SPIE (open access)
Links checked 21 Nov 2026.

What an MDDT is

FDA describes a Medical Device Development Tool as a scientifically validated tool that helps develop and evaluate devices. It can be a clinical outcome assessment, a biomarker test, or a non-clinical method or model. Once a tool is qualified for a specific use, any device maker can use it for that use, and FDA reviewers accept it without re-checking its suitability. An MDDT supports decisions about devices; it is not a device itself.[1]

How eeDAP went through the program

  • Oct 2016: the WSI Working Group lead announced that eeDAP would be submitted to the MDDT program and offered to document the process for the community.
  • Jan 2017: a draft proposal was shared with the group.
  • May 2017: FDA accepted the proposal into the program as MDDT031.
  • Dec 2017: an update linked the eeDAP studies to a new "high-throughput truthing" project.[2][3]

What you can use eeDAP for

  • Run reader studies that compare pathologists on glass slides with the same fields on whole slide images.
  • Test how scanner image quality changes diagnostic accuracy.
  • Collect expert annotations ("truthing") to validate AI algorithms.

The software was updated after the 2014 paper to work with more cameras, stages and image formats.[4]

Key publications

  1. 2014Gallas BD, et al. Evaluation environment for digital and analog pathology: a platform for validation studies. J Med Imaging. 2014.
    DOI: 10.1117/1.JMI.1.3.037501 · PubMed 26158076 · Free full text (PMC)
  2. 2014Gallas BD, et al. eeDAP: an evaluation environment for digital and analog pathology. Proc SPIE. 2014.
    DOI: 10.1117/12.2044443 · PubMed 28845079 · Free full text (PMC)

Identifiers checked against PubMed and the publishers' DOI records, 22 Nov 2026.

Sources

  1. FDA MDDT program · www.fda.gov · Government source
  2. Archived copy of the original page (3 Jun 2023) · web.archive.org · Archived original
  3. Blog index (archived) · web.archive.org · Archived original
  4. EeDAP on GitHub · github.com · Official site

About this page

This was an October 2016 post on the WSI Working Group blog, written by the group lead. We rewrote it as a guide to eeDAP and the MDDT program, with dates from later posts.